Ian Peikon
Venture Partner at Lux Capital
Seattle, Washington
Overview
Work Experience
Co-Founder & Co-Chief Executive Officer
2020 - Current
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Raised $96,000,000.00 from Bristol-Myers Squibb, Alexandria Venture Investments, Lux Capital, Evotec, Dolby Family Ventures, Two Sigma Ventures and The Column Group.
Board Member
2022
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Raised $165,000,000.00 from CRV, RA Capital Management, Pappas Capital, DCVC Bio, SoftBank Vision Fund, Pivotal bioVenture Partners, M Ventures, Surveyor Capital, Lux Capital and Neotribe Ventures.
Venture Partner
2019
Lux Capital is an investment firm that invests in counter-conventional, seed-stage science and technology ventures.
Co-Founder & SAB Member
2018 - 2022
non-viral gene therapy delivery systems - acquired by Aera Therapeutics
Co-Founder & Director, Platform Biology & Technology
2015 - 2019
I was part of the founding team of Kallyope and led the platform for new target discovery.
Kallyope uses the science of gut-brain biology to create medicines that transform human health.
Raised $487,200,000.00 from Bill & Melinda Gates Foundation.